Breast tumor with extensive tissue death (infarction)
This breast cancer diagnosis at a glance
- Subtype
- Invasive Ductal Carcinoma
- Biomarkers
- Oestrogen receptor-positive; HER2 equivocal; confirmatory HER2 FISH was not performed
- Sex
- Female
- Treatment
- hormone therapy
- Outcome
- Responding Well
Treatment course, step by step
- An ultrasound-guided vacuum-assisted biopsy excision established the diagnosis.
- She declined definitive surgery and began letrozole, which was later changed to tamoxifen because of osteoporosis.
What happened, in summary
A woman in her 80s with mild dementia noticed a lump in the outer part of her right breast that had been present for about 3 months. The 20 mm mass felt firm but was not painful, red, or inflamed. Ultrasound initially showed a mainly cystic lesion without a clear solid component.
A core biopsy obtained mostly dead, infarcted tissue and did not provide a definite diagnosis. Surgical excision was recommended, but she declined. Three months later, when the mass had become smaller, she agreed to an ultrasound-guided vacuum-assisted biopsy excision.
This larger tissue sample found a 3 mm area of grade 3 invasive ductal carcinoma within extensively infarcted breast tissue. The cancer was estrogen receptor-positive. HER2 testing was equivocal, but confirmatory FISH testing was not performed. The amount of viable cancer was small, but the diagnosis was invasive breast cancer rather than a benign cyst.
She again declined definitive breast surgery. Instead, she chose hormone treatment. Letrozole was started and was later changed to tamoxifen because osteoporosis made continued aromatase-inhibitor treatment less suitable.
At 1.5 years of clinical follow-up, there was no evidence of a remaining breast mass. A formal stage was not assigned, but she continued to respond to endocrine treatment without a clinically detectable residual tumor.
The first core biopsy sampled mainly infarcted tissue and therefore did not provide a definite diagnosis. The larger vacuum-assisted sample was essential because only a very small focus of living cancer remained.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- ER Positive Breast Cancer 242 stories
- Hormone Therapy for ER Positive Breast Cancer 136 stories
- Hormone Therapy for Breast Cancer 447 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer